NCT00759291View on ClinicalTrials.gov

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2006

Primary Completion Date

December 1, 2017

Study Completion Date

December 30, 2017

Conditions
Metabolic Syndrome
Interventions
DRUG

acipimox

250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit

DRUG

Placebo

1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT00759291 - The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome | Biotech Hunter | Biotech Hunter